Article

Ranibizumab approved for use in Europe

Basel, Switzerland-The European Union has approved ranibizumab (Lucentis, Genentech) as a new treatment for patients with wet age-related macular degeneration (AMD).

Basel, Switzerland-The European Union has approved ranibizumab (Lucentis, Genentech) as a new treatment for patients with wet age-related macular degeneration (AMD).

The decision came 11 months after submission and applies to all 27 member states as well as Iceland and Norway. The company has said it will launch the drug in European countries throughout 2007 and 2008.

The drug is approved for use in Switzerland, India, and the United States. It is the first therapy shown in clinical trials to improve vision and in patients with wet AMD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.